Effects of Restrictive Fluid Strategy on Postoperative Oliguric Pancreatic Surgery Patients

Sponsor
Uppsala University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03553394
Collaborator
(none)
200
1
2
33
6.1

Study Details

Study Description

Brief Summary

Reduced urinary output is a common postoperative issue for patients going through major surgery such as pancreatic surgery. Commonly this is treated by increasing fluid administration to the patients and sometimes also diuretics. However, overloading patients with fluid also have several risks and known complications. Studies have also shown that a short period of decreased urinary output in the postoperative period do not have an increased incidence of acute renal failure. The aim of our study is to investigate the difference in renal function and postoperative complications associated with fluid overload on these patients that are randomized to either receiving a fluid bolus directly when urinary output decreases or to await for a maximum of four hours to see if urinary output increases spontaneously.

Condition or Disease Intervention/Treatment Phase
  • Drug: Ringer's Acetate
N/A

Detailed Description

Patents after pancreatic surgery will be included in the study. Oliguric patients (urine output <0.5 ml/kg/h) will be randomized to fluid bolus (5ml/kg Ringer's Acetate in 30 minutes) or no intervention. Primary outcome is difference in urine output two hours after the fluid bolus or no intervention.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomized to either receive a fluid bolus immediately when urinary output is decreased for two consecutive hours or to await fluid bolus therapy for two more hours.Patients will be randomized to either receive a fluid bolus immediately when urinary output is decreased for two consecutive hours or to await fluid bolus therapy for two more hours.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effects on Fluid Balance and Renal Function Using a Restrictive Fluid Strategy in the Postoperative Setting in Patients With Low Urinary Output Undergoing Pancreatic Surgery
Actual Study Start Date :
Oct 1, 2018
Anticipated Primary Completion Date :
Dec 31, 2020
Anticipated Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard of care group

Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).

Drug: Ringer's Acetate
Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
Other Names:
  • Ringer Acetate
  • No Intervention: Expectant management group

    Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.

    Outcome Measures

    Primary Outcome Measures

    1. Urinary output [2 hours]

      Difference in urinary output two hours after giving the patient a fluid bolus (Control Group) or awaiting fluid bolus (interventional Group)..

    Secondary Outcome Measures

    1. Renal function [48 hours]

      Renal function after 48 hours

    2. Cumulative fluid balance [48 hours]

      Difference in cumulative fluid balance

    3. Postoperative complications [90 days]

      Frequency of postoperative complications in both groups

    4. Renal replacement therapy [Up to 90 days]

      The need for renal replacement therapy during the hospital stay

    5. Mortality [90 days]

      90-day mortality in both groups

    6. Inotropy [1 week]

      Postoperative need of inotropic therapy during the stay in the postoperative department

    7. Vasopressin (ADH) [1 day]

      Levels of vasopressin in serum immediately before and after the operation

    8. S-osmolality [1 day]

      S-osmolality immediately before and after the operation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients going through pancreatic surgery.
    Exclusion Criteria:
    • If not oliguric (urinary output <0,5 mls/kg/h) during their stay in the postoperative department

    • Hemodynamic instability (the need for >0,1 microgram/kg/min of norepinephrine to keep an acceptable mean arterial pressure based on the patients starting mean arterial pressure).

    • Patients that do not want to be a part of the study.

    • <18 years old

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Central ICU (CIVA), Uppsal university hospital Uppsala Sweden 75185

    Sponsors and Collaborators

    • Uppsala University

    Investigators

    • Principal Investigator: Miklos Lipcsey, MD, PhD, Uppsala University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Uppsala University
    ClinicalTrials.gov Identifier:
    NCT03553394
    Other Study ID Numbers:
    • 2018/147
    First Posted:
    Jun 12, 2018
    Last Update Posted:
    May 31, 2019
    Last Verified:
    May 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 31, 2019